{"organizations": [], "uuid": "b88a6455d864bafd097ca8dcad9a418fcbeedc8b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-cidara-reports-positive-topline-re/brief-cidara-reports-positive-topline-results-from-phase-2-strive-trial-of-lead-antifungal-rezafungin-idUSASC09SR7", "country": "US", "domain_rank": 408, "title": "BRIEF-Cidara Reports Positive Topline Results From Phase 2 Strive Trial Of Lead Antifungal Rezafungin", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-19T13:42:00.000+02:00", "replies_count": 0, "uuid": "b88a6455d864bafd097ca8dcad9a418fcbeedc8b"}, "author": "", "url": "https://www.reuters.com/article/brief-cidara-reports-positive-topline-re/brief-cidara-reports-positive-topline-results-from-phase-2-strive-trial-of-lead-antifungal-rezafungin-idUSASC09SR7", "ord_in_thread": 0, "title": "BRIEF-Cidara Reports Positive Topline Results From Phase 2 Strive Trial Of Lead Antifungal Rezafungin", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "cidara therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 42 AM / Updated 3 minutes ago BRIEF-Cidara Reports Positive Topline Results From Phase 2 Strive Trial Of Lead Antifungal Rezafungin Reuters Staff March 19 (Reuters) - Cidara Therapeutics Inc: * CIDARA THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 STRIVE TRIAL OF LEAD ANTIFUNGAL REZAFUNGIN * CIDARA THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 STRIVE TRIAL OF LEAD ANTIFUNGAL REZAFUNGIN * CIDARA THERAPEUTICS INC - ‍PHASE 3 STUDIES FOR BOTH TREATMENT AND PREVENTION ON TRACK TO START MID-2018​ * CIDARA THERAPEUTICS INC - PHASE 3 STUDIES FOR BOTH TREATMENT AND PREVENTION ON TRACK TO START MID-2018 * CIDARA THERAPEUTICS - ‍FAVORABLE SAFETY,TOLERABILITY,EFFICACY OBSERVED IN ONCE-WEEKLY ECHINOCANDIN FOR DIFFICULT-TO-TREAT INVASIVE FUNGAL INFECTIONS​ * CIDARA THERAPEUTICS INC - ‍STRIVE MET ALL OF ITS PRIMARY OBJECTIVES​ * CIDARA THERAPEUTICS INC - ‍THERE WERE NO CONCERNING TRENDS IN ADVERSE EVENTS OBSERVED​ * CIDARA THERAPEUTICS-THERE WERE 2 SERIOUS ADVERSE EVENTS POSSIBLY RELATED TO STUDY DRUG: ONE IN GROUP 2, ONE IN GROUP 3; BOTH PATIENTS FULLY RECOVERED​ * CIDARA THERAPEUTICS INC - ‍ PHASE 3 RESPECT PROPHYLAXIS TRIAL EXPECTED TO PRODUCE AN INTERIM FUTILITY READ-OUT IN 2019, PROVIDE TOPLINE RESULTS IN 2020​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-19T13:42:00.000+02:00", "crawled": "2018-03-19T13:47:17.060+02:00", "highlightTitle": ""}